INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04580485. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
Study identification
- NCT ID
- NCT04580485
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 54 participants
Conditions and interventions
Conditions
- Ovarian Cancer
- Bladder Cancer
- Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Cancer
- Castration Resistant Prostate Cancer
- Colorectal Cancer
- Gastric/ Gastroesophageal Junction
- Hepatocellular Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Squamous Carcinoma of the Anal Canal
Interventions
- INCB106385 Drug
- INCMGA00012 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2021
- Primary completion
- Jan 21, 2024
- Completion
- Jan 21, 2024
- Last update posted
- Jul 10, 2025
2021 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | West Hollywood | California | 90048 | — |
| University of Maryland-Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15232 | — |
| Md Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04580485, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04580485 live on ClinicalTrials.gov.